

University of Groningen

Erratum: Continuous and Daily Oral Immunotherapy for Peanut Allergy

Vickery, Brian P.; Vereda, Andrea; Nilsson, Caroline; du Toit, George; Shref, Wayne G.; Burks, A. Wesley; Jones, Stacie M.; Fernandez-Rivas, Montserrat; Blumchen, Katharina; Hourihane, Jonathan O'B.

Published in:
Journal of Allergy and Clinical Immunology: In Practice

DOI:
[10.1016/j.jaip.2021.11.019](https://doi.org/10.1016/j.jaip.2021.11.019)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Vickery, B. P., Vereda, A., Nilsson, C., du Toit, G., Shref, W. G., Burks, A. W., Jones, S. M., Fernandez-Rivas, M., Blumchen, K., Hourihane, J. O'B., Beyer, K., Anagnostou, A., Assa'ad, A. H., Ben-Shoshan, M., Bird, J. A., Carr, T. F., Ciaccio, W., Casale, T. B., Chong, H. J., ... Sprickelman, A. B. (2022). Erratum: Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study (vol 9, pg 1879, 2021). *Journal of Allergy and Clinical Immunology: In Practice*, 10(2), 647-650. <https://doi.org/10.1016/j.jaip.2021.11.019>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Corrections



With regard to the article in the May 2021 issue entitled “Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study” (J Allergy Clin Immunol Pract 2021;9(5):1879-1889.e14), the authors report that several investigators were not included in the author byline. Additionally, the table reporting the Principal Investigators and Participating Sites listed in the Online Repository was incorrect. The correct author byline list and Online Repository Table are provided. These errors do not affect the conclusions detailed in the manuscript. The authors apologize for any inconvenience caused. The author byline has been updated in the online posting of the article and should have read as follows:

“Brian P. Vickery, MD^{a*}, Andrea Vereda, MD, PhD^{b*}, Caroline Nilsson, MD, PhD^{c*}, George du Toit, MD^{d*}, Wayne G. Shreffler, MD, PhD^{e*}, A. Wesley Burks, MD^{f*}, Stacie M. Jones, MD^{g*}, Montserrat Fernández-Rivas, MD, PhD^{h*}, Katharina Blümchen, MD^{i*}, Jonathan O’B. Hourihane, MD^{j,k*}, Kirsten Beyer, MD^{l*}, Aikaterini Anagnostou, MD (Hons), MSc, PhD^m, Amal H. Assa’ad, MDⁿ, Moshe Ben-Shoshan, MD, MSc^o, J. Andrew Bird, MD^p, Tara F. Carr, MD^q, Warner W. Carr, MD, FACP, FACAAI, FAAAAI^r, Thomas B. Casale, MD^s, Hey Jin Chong, MD, PhD, FAAAAI^t, Christina E. Ciaccio, MD, MSc^u, Morna J. Dorsey, MD, MMS^v, Stanley M. Fineman, MD, MBA^w, Stephen B. Fritz, MD^x, Alexander N. Greiner, MD, CPI, FAAAAI^y, Leon S. Greos, MD^z, Frank C. Hampel Jr., MD^{aa}, Maria Dolores Ibáñez, MD, PhD^{bb}, David K. Jeong, MD^{cc}, Douglas T. Johnston, DO, FAAAAI, FACAAI^{dd}, Rita Kachru, MD^{ee}, Edwin H. Kim, MD, MS^{ff}, Bruce J. Lanser, MD, MPH^{gg}, Stephanie A. Leonard, MD^{hh}, Mary C. Maier, MDⁱⁱ, Lyndon E. Mansfield, MD^{jj}, Antonella Muraro, MD, PhD^{kk}, Jason A. Ohayon, MD^{ll}, Joanna N.G. Oude Elberink, MD, PhD^{mm}, Daniel H. Petroni, MD, PhDⁿⁿ, Jacqueline A. Pongracic, MD^{oo}, Jay M. Portnoy, MD^{pp}, Rima Rachid, MD^{qq}, Ned T. Rupp, MD^{rr}, Georgiana M. Sanders, MD, MS^{ss}, Hemant P. Sharma, MD, MHS^{tt}, Vibha Sharma, MD^{uu}, Ellen R. Sher, MD^{vv}, Lawrence Sher, MD, FAAP, FAAAAI, FACAAI^{ww}, Sayantani B. Sindher, MD^{xx}, Dareen Siri, MD, FAAAAI, FACAAI^{yy}, Jonathan M. Spergel, MD, PhD^{zz}, Aline B. Sprickelman, MD, PhD^{aaa}, Gordon L. Sussman, MD, FRCP (C), FACP, DIP.ABIM, FAAAAI^{bbb}, Marina Tsoumani, MD^{ccc}, Pooja Varshney, MD^{ddd}, Girish Vitalpur, MD^{eee}, Julie Wang, MD^{fff}, William H. Yang, MD, FRCPC, FAAAAI^{ggg}, José Manuel Zubeldia, MD, PhD^{hhh}, Alex Smith, BSc^{iii*}, Robert Ryan, PharmD, PhD^{b*}, and Daniel C. Adelman, MD^{iii,iii*}”

The updated affiliations list is as follows:

*Manuscript writing group

^aEmory University School of Medicine, Atlanta, Ga

^bAimmune Therapeutics, London, United Kingdom

^cClinical Science and Education, Karolinska Institutet, Sachs’ Children and Youth Hospital, Stockholm, Sweden

^dGuy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom

^eMassachusetts General Hospital, Boston, Mass

^fDepartment of Pediatrics, University of North Carolina Food Allergy Initiative, Division of Allergy and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC

^gUniversity of Arkansas for Medical Sciences and Arkansas Children’s Hospital, Little Rock, Ark

^hAllergy Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain

ⁱAdolescent Medicine, Division of Allergology, Pneumology and Cystic Fibrosis, Goethe University Frankfurt, Frankfurt, Germany

^jPaediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin, Ireland

^kInfant Centre and Pediatrics and Child Health, University College Cork, HRB Clinical Research Facility-Cork, Cork, Ireland

^lDepartment of Pediatrics, Division of Pulmonology, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany

^mTexas Children’s Hospital, Main Hospital, Houston, Texas

ⁿCincinnati Children’s Hospital Medical Center, Cincinnati, Ohio

^oMcGill University Health Centre - Montreal Children’s Hospital, Montreal, Quebec, Canada

^pChildren’s Medical Center, Dallas, Texas

^qBanner University of Arizona Medical Center, Tucson, Ariz

^rAllergy & Asthma Associates of Southern California dba Southern California Research, Mission Viejo, Calif

^sUniversity of South Florida, Asthma, Allergy & Immunology Clinical Research Unit, Tampa, Fla

^tChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pa

^uComer Children's Hospital, Chicago, Ill

^vUniversity of California, San Francisco, San Francisco, Calif

^wAtlanta Allergy & Asthma Clinic, PA, Marietta, Ga

^xIdaho Allergy and Research, Eagle, Idaho

^yAllergy & Asthma Medical Group and Research Center, San Diego, Calif

^zColorado Allergy and Asthma Centers, PC, Denver, Colo

^{aa}Central Texas Health Research, New Braunfels, Texas

^{bb}Hospital Clínico San Carlos, Hospital Universitario Niño Jesús, Alergology Department, Madrid, Spain

^{cc}Virginia Mason Medical Center, Seattle, Wash

^{dd}Clinical Research of Charlotte, Charlotte, NC

^{ee}UCLA Medical Center, Santa Monica, Santa Monica, Calif

^{ff}University of North Carolina at Chapel Hill CTRC, Chapel Hill, NC

^{gg}National Jewish Health, Denver, Colo

^{hh}Rady Children's Hospital San Diego, San Diego, Calif

ⁱⁱBaker Allergy, Asthma and Dermatology Research Center, LLC, Portland, Ore

^{jj}Western Sky Medical Research, El Paso, Texas

^{kk}Azienda Ospedaliera di Padova – UOSD Allergie Alimentari, Padova, Italy

^{ll}Triple A Lab, Hamilton, Ontario, Canada

^{mmm}University Medical Center Groningen, Department of Internal Medicine, Division of Allergology, Groningen, Netherlands

ⁿⁿAsthma Inc. Clinical Research Center, Seattle, Wash

^{oo}Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill

^{pp}Children's Mercy on Broadway, Kansas City, Mo

^{qq}Boston Children's Hospital, Boston, Mass

^{rr}National Allergy and Asthma Research, LLC, N. Charleston, SC

^{ss}Michigan Medicine, Michigan Clinical Research Unit, Ann Arbor, Mich

^{tt}Children's National Medical Center, Washington, DC

^{uu}Central Manchester University Hospitals NHS Foundation Trust, Royal Manchester Children's Hospital, Manchester, United Kingdom

^{vv}Atlantic Research Center, LLC, Ocean, NJ

^{ww}Peninsula Research Associates, Inc., Rolling Hills Estates, Calif

^{xx}Sean N. Parker Center for Allergy and Asthma Research, LPCH at El Camino Hospital, Mountain View, Calif

^{yy}Sneeze, Wheeze, & Itch Associates, LLC, Normal, Ill

^{zz}The Children's Hospital of Philadelphia, Philadelphia, Pa

^{aaa}University Medical Center Groningen, Beatrix Children's Hospital, Department of Pediatric Pulmonology & Allergology, Groningen, Netherlands

^{bbb}Gordon Sussman Clinical Research, Inc., Toronto, Ontario, Canada

^{ccc}Manchester University NHS Foundation Trust –Wythenshawe Hospital, Manchester, United Kingdom

^{ddd} Specially for Children Allergy, Asthma, and Immunology Clinic, Austin, Texas

^{eee} Indiana University North Hospital, Riley Children's Specialists, Carmel, Ind

^{fff} Icahn School of Medicine at Mount Sinai, Clinical Research Unit, New York, NY

^{ggg} Ottawa Allergy Research Corporation, Ottawa, Ontario, Canada

^{hhh} Hospital General Universitario Gregorio Marañón, Alergology Department, Madrid, Spain

ⁱⁱⁱ Aimmune Therapeutics, Brisbane, Calif

^{jjj} Department of Medicine, University of California San Francisco, San Francisco, Calif

The updated Conflicts of Interest statement is as follows: "B. P. Vickery reports advisory board/consultant role with Aimmune Therapeutics, AllerGenis, FARE, and Reacta; site investigator role with Aimmune Therapeutics, DBV, Genentech, and Regeneron; research grants from FARE and the National Institute of Allergy and Infectious Diseases (NIAID). A. Vereda is an employee and stockholder of Aimmune Therapeutics. C. Nilsson reports grants to institution and advisory board fees from Aimmune Therapeutics and speakers fees from MEDA, ALK, Thermo Fisher, and GlaxoSmithKline. G. du Toit reports research grants to institution and advisory board fees from Aimmune Therapeutics. W. G. Shreffler reports membership on Scientific Advisory Board, Aimmune Therapeutics, and consultancies for DBV Technologies and Sanofi. A. W. Burks has received research support, advisory board fees, and lecture honoraria/consultation fees from Aimmune Therapeutics. S. M. Jones reports advisory board fees from Aimmune Therapeutics and FARE; personal fees from DBV Technologies; clinical trials grants from Aimmune Therapeutics, DBV Technologies, Astellas, Sanofi, Regeneron, FARE, Genentech, and the National Institutes of Health-NIAID. M. Fernández-Rivas reports consultancies for Aimmune Therapeutics, DBV, Novartis, and SPRIM; research funding from the European Commission and Ministry of Economy and Competitiveness and The National Institute of Health Carlos III of Spanish government; working on speakers bureau for ALK, Allergy Therapeutics, Diater, Fundacion SEAIC, HAL Allergy, and Thermo Fisher Scientific. K. Blümchen reports consulting fees for Aimmune Therapeutics, DBV Technologies, Bencard Allergie, and HAL Allergy; working on speakers bureau for Aimmune Therapeutics, DBV Technologies, HAL Allergy, Nutricia, Thermo Fisher Scientific, ALK, Allergopharma, and Nestle; and conducting clinical trials for Aimmune Therapeutics, DBV Technologies, and Hipp. J. O'B. Hourihane reports advisory board fees from Aimmune Therapeutics; working on speakers bureau for Aimmune Therapeutics, DBV Technologies, Nutricia, and Mead Johnson; and grants to institution/research funding and clinical trials within the past 2 years with Aimmune Therapeutics and DBV Technologies. K. Beyer reports advisory board/consulting fees from Aimmune Therapeutics, ALK, Bausch & Lomb, Bencard, Danone, Hycor, Infectopharm, Mabylon, Meda Pharma, Mylan, and Nestle; working on speakers bureau for Aimmune Therapeutics, Allergopharma, Bencard, Danone, Di-Text, Hammerund Rall Media, Infectopharm, Meda Pharma, Med Update, Nestle, and Nutricia; and research grants from Aimmune, ALK, Danone, DBV, Good Mills, Hipp, Hycor, Infectopharm, Nutricia, ThermoFisher, and VDI. A. Anagnostou reports institutional grant funding from Aimmune Therapeutics and FARE; advisory board participation for DBV Technologies; and personal fees from ALK. A. H. Assa'ad reports institutional grant funding from Aimmune Therapeutics, DBV Technologies, Sanofi/Aventis, AbbVie, Astellas, NIH, and FARE; and has a patent for Genetic Markers of Food Allergy with royalties paid to Hoth Therapeutics. M. Ben-Shoshan reports consulting fees from Novartis; honoraria for lectures for Novartis and Stallergenes Greer Canada. J. A. Bird reports institutional grants and personal fees for advisory boards and investigator meetings from Aimmune Therapeutics; grants from FARE, NIH-NIAID, Genentech, DBV Technologies, and Astellas; personal fees from FARE, Nutricia North America, Pharm-Olam International LTD, Pfizer Pharmaceuticals, Prota Therapeutics, Allergy Therapeutics, LTD, AllerGenis, Abbott Nutrition International, DBV Technologies, Vindico Medical Education, WebMD, Novartis, and Before Brands. T. Carr reports study funding from Aimmune Therapeutics; honoraria from Regeneron. W. W. Carr reports personal fees from AstraZeneca, DBV technologies, MERZ, TEVA, Regeneron, Optinose, Glenmark Pharmaceuticals, and Sanofi. T. B. Casale reports his position as Chief Medical Advisor of FARE. H. J. Chong reports grant funding from Aimmune Therapeutics; personal fees from DBV Technologies. C. E. Ciaccio reports advisory board participation with Aimmune Therapeutics, Novartis, and DBV Technologies. M. J. Dorsey reports no conflicts. S. M. Fineman reports clinical research for Aimmune Therapeutics, DBV Technologies, Alladapt, and Biocryst; speaker honorarium for Biocryst and Takeda. S. B. Fritz reports study funding from Aimmune Therapeutics. A. Greiner reports research support from Nestlé, Sanofi Aventis, Alladapt, and Aimmune Therapeutics. L. S. Greos reports no conflicts. F. C. Hampel Jr reports no conflicts. M. D. Ibáñez reports grants from Aimmune Therapeutics and National Instituto Salud Carlos III; honoraria for paid lectures from Merck, LETI, ROXALL, CIRCASSIA, and Sanofi. D. Jeong reports personal fees from Before Brands. D. T. Johnston reports personal fees from Aimmune and DBV Technologies. R. Kachru reports no conflicts. E. Kim reports personal fees from DBV Technologies, Kenota Health, ALK, Ukko, Inc., AllerGenis, Duke Clinical Research Institute, Belhaven Pharma, Nutricia; grant support from FARE, NIH/NIAID, NIH/NCCIH. B. Lanser reports grants and personal fees from Aimmune Therapeutics, DBV Technologies, and Genentech; grants from Regeneron and NIH/NIAID-sponsored CoFAR; personal fees from Hycor, AllerGenis, and GSK. S. A. Leonard reports personal fees from Aimmune Therapeutics, Food Allergy Research & Education, American Academy of Pediatrics, University of California Davis, Texas Allergy, Asthma, & Immunology Society,

Oceanside Publications Inc., and LabCorp; membership on the International FPIES Association medical advisory board. M. C. Maier reports no conflicts. L. E. Mansfield. M. A. Muraro reports personal fees from Nestlé Health Institute, Aimmune Therapeutics, Nestlé Purina, Viartis, DBV Technologies, and HAL Allergy. J. A. Ohayon reports no conflicts. J. N. G. Oude Elberink reports grants from Blueprint, Pure IMS, and Sanofi; consultancy fees from Blueprint, Takeda, Behring, Novartis, and Viartis. D. H. Petroni reports no conflicts. J. A. Pongracic reports institutional funding and provision of study medications from Aimmune Therapeutics and DBV Technologies. J. M. Portnoy reports institutional grant funding from Aimmune Therapeutics; consulting fees from Aimmune Therapeutics. R. Rachid reports grant funding from Aimmune Therapeutics, End Allergies Together, Food Allergy Research & Education, Boston Children's Hospital, and Food Allergy Fund; an issued patent for microbial therapies in food allergy. N. T. Rupp reports no conflicts. G. Sanders reports grant funding from Aimmune Therapeutics, DBV Technologies, Regeneron Pharmaceuticals, and Aimmune Pharmaceuticals. H. P. Sharma reports no conflicts. V. Sharma reports institutional grant funding and consulting fees with Aimmune Therapeutics. E. R. Sher reports grant funding, consulting fees, and honoraria from Aimmune Therapeutics. L. D. Sher reports no conflicts. S. B. Sindher reports grant funding from NIH, Regeneron, DBV Technologies, Aimmune Therapeutics, Novartis, CoFAR, and FARE; personal fees from FARE; advisory committee with AstraZeneca and DBV Technologies. D. D. Siri reports honoraria from Aimmune Therapeutics. J. M. Spergel reports grant funding from Aimmune Therapeutics, Regeneron/Sanofi, NIH, Food Allergy Research Education, and DBV Technologies; personal fees from Regeneron/Sanofi, Food Allergy Research Education, and DBV Technologies. A. B. Sprickelman reports grant funding from Aimmune Therapeutics. G. L. Sussman reports no conflicts. M. Tsoumani reports institutional grant funding from Aimmune Therapeutics; honoraria and travel assistance from Allergy Therapeutics. P. Varshney reports institutional grant funding from Aimmune Therapeutics, DBV Technologies, and MJ&M Foundation via Dell Children's Foundation; grant funding and personal fees from Food Allergy Research & Education; non-financial support from American Academy of Pediatrics, Texas Allergy, Asthma, & Immunology Society, and American Academy of Allergy, Asthma, & Immunology; personal fees from Dell Children's Medical Center of Central Texas; stock ownership in Nestlé prior to relationship with Aimmune (Aimmune was acquired by Nestlé in late 2020). G. Vitalpur reports no conflicts. J. Wang reports institutional grant funding from Aimmune Therapeutics, DBV Technologies, Regeneron, Genentech, and NIH; royalties from UpToDate; support for attending meetings/travel from AAP, AAAAi/ACAAI Joint Task Force for Practice Parameters; advisory board participation from DBV Technologies, ALK Abello, and Genentech; unpaid leadership roles for AAP Section on Allergy and Immunology (Chair) and AAAAi Anaphylaxis Dermatitis Drug Allergy Interest Section (Vice Chair); stock options in JDP Therapeutics. W. H. Yang reports research grants from Amgen, Anaptysbio, Novartis, GSK, AstraZeneca, Shire/Takeda, CSL Behring, ALK, Pharming, Pharvaris, Regeneron, Sanofi, Glenmark, Galderma, Celgene, and Providence; honorarium from Novartis, Merck, AstraZeneca, Shire/Takeda, and CSL Behring; consulting fees as medical advisory board member from Shire/Takeda, CSL Behring, Novartis, Merck, and Sanofi. J. M. Zubeldia Ortuño reports grant funding from Aimmune Therapeutics. A. Smith and R. Ryan are employees and stockholder of Aimmune Therapeutics. D. C. Adelman is an employee and stockholder of Aimmune Therapeutics and has patents pending for the following: US 16/542,198, PCT/US2019/046706, US 16/721,805, and PCT/US2019/067634."

Additionally, the Online Repository file has been replaced in the online posting of the article with a revised list of participating sites.

The authors regret the error.



With regard to the article in the January 2021 issue entitled "Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure" (J Allergy Clin Immunol Pract 2021;9(1):582-584.e1), the authors report that they failed to acknowledge the funding sources for their article. The funding statement should have read as follows: "J. Peter receives funding from the National Institutes for Health (NIH K43TW011178), the South African Medical Research Council, and the National Research Foundation. The IMARI-Africa project is part of the EDCTP2 programme supported by the European Union (grant number TMA2017SF-1981). The IMARI-SA Registry and Biorepository is supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH (award number R01AI152183)." The authors regret the error.